Schering's diagnostic sales beat expectations:
This article was originally published in Clinica
Executive Summary
German company Schering had full-year diagnostic sales of Euro1,040 million ($1,013 million), up 18% and "far ahead of expectations", the company said. Berlin-based Schering attributed the good result to a substantial growth in volume sales, as well as the recovery of the Asian currencies and relatively stable prices in Japan. X-ray contrast media sales increased 17% to Euro646 million, while sales of Magnevist, a contrast media for MRI, rose 18% to Euro233 million. During the year, the company expanded into radiopharmaceuticals with the acquisition of US company Diatide and CIS of France.